Synaptic proteins have been evaluated in exploratory CSF cohorts and shown to be altered in subjects with sporadic AD, both by mass spectrometry [12–16] and immunoassays [8, 17–23] but the first steps towards patient monitoring have largely been restricted to CSF neurogranin measurements in clinical trials [24, 25]. Here, NRGN is linked to Alzheimer disease.